Vitrolife AB (VITR) - Total Liabilities
Based on the latest financial reports, Vitrolife AB (VITR) has total liabilities worth Skr3.17 Billion SEK (≈ $340.82 Million USD) as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore Vitrolife AB long-term investment allocation to see how much of total assets are deployed in long-term investments.
Vitrolife AB - Total Liabilities Trend (2000–2025)
This chart illustrates how Vitrolife AB's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see VITR current and non-current assets.
Vitrolife AB Competitors by Total Liabilities
The table below lists competitors of Vitrolife AB ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Norwegian Air Shuttle ASA
OL:NAS
|
Norway | Nkr38.28 Billion |
|
Innuovo Technology Co Ltd Class A
SHE:000795
|
China | CN¥1.71 Billion |
|
Dalian Bio-Chem Co Ltd
SHG:603360
|
China | CN¥1.94 Billion |
|
National Vision Holdings Inc
NASDAQ:EYE
|
USA | $1.09 Billion |
|
Sino Prima Gas Technology Co Ltd
SHE:300483
|
China | CN¥3.38 Billion |
|
MPC Container Ships ASA
OL:MPCC
|
Norway | Nkr599.75 Million |
|
Telling Telecommunication Holding Co Ltd
SHE:000829
|
China | CN¥27.19 Billion |
Liability Composition Analysis (2000–2025)
This chart breaks down Vitrolife AB's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See VITR equity to assets ratio to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.64 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.39 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.28 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Vitrolife AB's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Vitrolife AB (2000–2025)
The table below shows the annual total liabilities of Vitrolife AB from 2000 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | Skr3.23 Billion ≈ $347.49 Million |
-15.14% |
| 2024-12-31 | Skr3.81 Billion ≈ $409.48 Million |
+5.52% |
| 2023-12-31 | Skr3.61 Billion ≈ $388.06 Million |
-5.38% |
| 2022-12-31 | Skr3.81 Billion ≈ $410.12 Million |
-6.77% |
| 2021-12-31 | Skr4.09 Billion ≈ $439.93 Million |
+1319.05% |
| 2020-12-31 | Skr288.07 Million ≈ $31.00 Million |
-15.54% |
| 2019-12-31 | Skr341.06 Million ≈ $36.70 Million |
+69.47% |
| 2018-12-31 | Skr201.25 Million ≈ $21.66 Million |
+3.86% |
| 2017-12-31 | Skr193.78 Million ≈ $20.85 Million |
-15.79% |
| 2016-12-31 | Skr230.11 Million ≈ $24.76 Million |
+7.39% |
| 2015-12-31 | Skr214.27 Million ≈ $23.06 Million |
-20.61% |
| 2014-12-31 | Skr269.91 Million ≈ $29.05 Million |
+63.38% |
| 2013-12-31 | Skr165.21 Million ≈ $17.78 Million |
-9.83% |
| 2012-12-31 | Skr183.22 Million ≈ $19.72 Million |
+49.11% |
| 2011-12-31 | Skr122.88 Million ≈ $13.22 Million |
+19.23% |
| 2010-12-31 | Skr103.06 Million ≈ $11.09 Million |
+118.12% |
| 2009-12-31 | Skr47.25 Million ≈ $5.08 Million |
-6.02% |
| 2008-12-31 | Skr50.27 Million ≈ $5.41 Million |
+9.11% |
| 2007-12-31 | Skr46.08 Million ≈ $4.96 Million |
-8.57% |
| 2006-12-31 | Skr50.40 Million ≈ $5.42 Million |
+44.32% |
| 2005-12-31 | Skr34.92 Million ≈ $3.76 Million |
-0.13% |
| 2004-12-31 | Skr34.96 Million ≈ $3.76 Million |
-13.80% |
| 2003-12-31 | Skr40.56 Million ≈ $4.36 Million |
-47.40% |
| 2002-12-31 | Skr77.11 Million ≈ $8.30 Million |
-10.65% |
| 2001-12-31 | Skr86.30 Million ≈ $9.29 Million |
+114.93% |
| 2000-12-31 | Skr40.15 Million ≈ $4.32 Million |
-- |
About Vitrolife AB
Vitrolife AB (publ) provides assisted reproduction products in Europe, the Middle East, Africa, Asia-Pacific, and the Americas. It offers sperm processing, oocyte retrieval needles, micromanipulation pipettes, time-lapse systems, and evaluation tools, laser and imaging systems, IVF media and oil, embryo transfer, cryopreservation, and genomics kits. The company also provides eWitness and Labware … Read more